VYGR - NASDAQ

Voyager Therapeutics, Inc.

VYGR·NASDAQ

$3.59

+1.1%

HealthcareBiotechnology

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$216.91M

EPS-2.0400

P/E Ratio-1.93

Earnings Date08/05/2026

252.28M

Assets

-36%

3Y+58.0%

5Y-4.0%

10Y+33.0%

56.20M

Total Liabilities

-40%

3Y-44.0%

5Y-48.0%

10Y+5.0%

196.08M

Total Equity

-35%

3Y+232.0%

5Y+27.0%

10Y+44.0%

Voyager Therapeutics, Inc. Funding & Solvency Profile

VYGR · NASDAQ

Current Assets

Cash & Cash Equivalents65.30M

Net Receivables1.76M

Inventory0.00

Other Current Assets4.48M

Total Current Assets203 M

Non-Current Assets

Property, Plant & Equipment41.61M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets7.98M

Total Non-Current Assets50 M

Total Assets

252.28M

Financial Health Analysis

Current Ratio

7.64x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.29x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

176 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

80% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Voyager Therapeutics, Inc. Balance Sheet

VYGR • NASDAQ

Voyager Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	65.3M	71.4M	68.8M	99M	117.4M	104.4M	86M	46.9M	31.5M	36.6M	31.3M	7M	135K
Short-Term Investments	131.1M	195.3M	162.1M	19.9M	15.1M	76.7M	195.5M	108.9M	137.5M	137.8M	163M	0.0	0.0
Cash & Short-Term Investments	196.4M	266.7M	230.9M	118.8M	132.5M	181.1M	281.5M	155.8M	169.1M	174.4M	224.3M	7M	135K
Net Receivables	1.8M	4.5M	84.5M	639K	748K	8M	18.7M	201K	0.0	2.3M	411K	0.0	0.0
Accounts Receivables	1.8M	1.5M	80.2M	639K	732K	8M	18.5M	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	3M	4.3M	0.0	16K	0.0	0.0	201K	0.0	2M	411K	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	2.2M	5.1M	1.9M	1.5M	-29.2M	0.0	0.0
Prepaids	0.0	2.8M	1.7M	779K	1.7M	1.5M	2.2M	5.1M	1.3M	1.6M	764K	18K	0.0
Other Current Assets	4.5M	2.9M	2.6M	4.2M	1.7M	7.2M	2M	1.4M	2.2M	430K	382K	1.3M	0.0
Total Current Assets	202.7M	276.8M	319.7M	124.5M	136.7M	197.8M	304.7M	162.5M	171.8M	178.8M	195.9M	8.4M	135K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	41.6M	47.7M	30M	33.3M	55.4M	61.5M	46.5M	12.8M	10.3M	7.9M	3.2M	2.8M	0.0
Long-Term Investments	0.0	65.7M	0.0	0.0	0.0	0.0	1.9M	628K	1.1M	1.4M	30M	0.0	0.0
Other Non-Current Assets	8M	2.9M	1.6M	1.5M	1.8M	2.3M	1.7M	1.1M	1.3M	1.5M	321K	335K	14K
Total Non-Current Assets	49.6M	116.2M	31.6M	34.9M	57.2M	63.8M	50.1M	14.5M	12.7M	10.8M	33.6M	3.1M	14K
Total Assets	252.3M	393.1M	351.3M	159.4M	193.9M	261.6M	354.8M	177M	184.5M	189.6M	229.5M	11.5M	149K
LIABILITIES
CURRENT LIABILITIES
Total Payables	5M	4M	1.6M	2.6M	574K	634K	4.1M	1M	1M	550K	612K	1.6M	950K
Accounts Payable	5M	4M	1.6M	2.6M	574K	634K	4.1M	1M	1M	550K	612K	1.6M	950K
Accrued Expenses	0.0	7.4M	10.2M	3.3M	5.9M	14.2M	5.7M	3.8M	3.4M	2.4M	1.3M	368K	90K
Short Term Debt	7.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9M
Capital Lease Obligations (Current)	0.0	7.2M	3.2M	2.8M	5.6M	4.2M	3.2M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	1.6M	24.4M	42.9M	59.4M	33.9M	0.0	47.2M	20.8M	3.4M	6.8M	19.6M	0.0	0.0
Other Current Liabilities	12.1M	6.8M	6.6M	4.6M	5M	7.7M	15.8M	6M	8.1M	4.1M	2.4M	552K	15K
Total Current Liabilities	26.5M	49.8M	64.5M	72.6M	51M	26.8M	76M	31.7M	15.9M	13.8M	23.9M	2.5M	4M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3M	0.0
Deferred Revenue (Non-Current)	0.0	6M	32.4M	6.5M	8.2M	0.0	194.5M	113M	31.6M	41.6M	55M	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	-47.2M	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	1M	1M	1M	1M	1M	37.1M	1M	6.7M	6.3M	5M	1.1M	1.6M	0.0
Total Non-Current Liabilities	29.7M	43.5M	50.5M	27.7M	47.8M	80.5M	179.2M	98.9M	34.5M	39.8M	36.5M	7.9M	3.9M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.9M
Capital Lease Obligations	28.7M	43.7M	20.3M	23.1M	44.2M	47.6M	34.2M	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	56.2M	93.3M	115M	100.3M	98.8M	107.3M	255.2M	130.6M	50.4M	53.6M	60.4M	10.3M	4M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	229.5M	22M	0.0
Common Stock	59K	55K	44K	38K	38K	37K	37K	32K	32K	26K	25K	1K	0.0
Additional Paid-In Capital	641.9M	626.3M	497.5M	452.7M	442.3M	430.3M	412.2M	315.6M	295M	226M	219.1M	0.0	0.0
Retained Earnings	-445.9M	-326.2M	-261.2M	-393.5M	-347.1M	-275.9M	-312.6M	-269.1M	-160.7M	-90M	-49.8M	-20.8M	-3.8M
Accumulated Other Comprehensive Income/Loss	32K	-407K	-48K	-219K	-138K	-134K	-104K	-133K	-287K	-52K	-251K	-22M	0.0
Total Stockholders' Equity	196.1M	299.8M	236.3M	59M	95.1M	154.3M	99.5M	46.4M	134.1M	135.9M	169.1M	1.1M	-3.8M
Total Equity	196.1M	299.8M	236.3M	59M	95.1M	154.3M	99.5M	46.4M	134.1M	135.9M	169.1M	1.1M	-3.8M
SUMMARY
Total Liabilities & Equity	252.3M	393.1M	351.3M	159.4M	193.9M	261.6M	354.8M	177M	184.5M	189.6M	229.5M	11.5M	149K
Total Investments	131.1M	261M	162.1M	19.9M	15.1M	76.7M	197.4M	109.6M	138.6M	139.1M	193M	0.0	0.0
Total Debt	36.5M	43.7M	20.3M	23.1M	44.2M	47.6M	34.2M	0.0	0.0	0.0	0.0	6.3M	2.9M
Net Debt	-28.8M	-27.6M	-48.5M	-75.8M	-73.3M	-56.8M	-51.9M	-46.9M	-31.5M	-36.6M	-31.3M	-730K	2.8M
Shares Outstanding	55,468,806	55,468,806	55,468,806	55,468,806	55,468,806	55,468,806	55,468,806	55,468,806	55,468,806	55,468,806	55,468,806	55,468,806	55,468,806

SEC Filings

VYGR - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 01, 2026	June 01, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 21, 2026	April 15, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 09, 2026	March 09, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 09, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 12, 2026	February 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 08, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 10, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 173 filings

Related Guides

Blog Categories

Continue your VYGR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.